SCHEMBL847661

SCHEMBL847661

CC(Cl)OS(=O)(=O)Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2332663 0.78
SCHEMBL2734238 0.75
SCHEMBL8555332 0.73
SCHEMBL27786735 0.73
SCHEMBL1596074 0.71
SCHEMBL8749474 0.71
SCHEMBL8666161 0.71
SCHEMBL29216597 0.69
SCHEMBL27571137 0.68
SCHEMBL10784181 0.67 TP53 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-59025373-A None JP disclosed
CN-122070276-A Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same 人类生物科学股份有限公司 2026-05-19 CN disclosed
US-20260124190-A1 METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2026-05-07 US disclosed
EP-4705289-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF Terran Biosciences Inc. (US) 2026-03-11 EP disclosed
US-20260055110-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS AZURA OPHTHALMICS LTD (IL) 2026-02-26 US disclosed
US-12441723-B2 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations RIGEL PHARMACEUTICALS, INC. (US) 2025-10-14 US disclosed
US-12357623-B2 Method for treating a disease or condition using a pyrazole compound or formulation thereof RIGEL PHARMACEUTICALS, INC. (US) 2025-07-15 US disclosed
US-20240382470-A1 Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus RIGEL PHARMACEUTICALS INC (US) 2024-11-21 US disclosed
WO-2024226691-A1 PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. (US) 2024-10-31 WO disclosed
CN-118510771-A IRAK inhibitors for the treatment of conditions associated with cytokine release associated with respiratory viral infection 里格尔药品股份有限公司 2024-08-16 CN disclosed
EP-0539493-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES. BODOR NICHOLAS S (US) 1993-05-05 EP disclosed
US-5177064-A TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1993-01-05 US disclosed
WO-1992017185-A1 TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1992-10-15 WO disclosed
US-5100887-A Bactericides HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
WO-1992000988-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES BODOR NICHOLAS S (US) 1992-01-23 WO disclosed
EP-0334853-A4 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY. BODOR NICHOLAS S 1990-02-26 EP disclosed
EP-0334853-A1 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY BODOR, Nicholas S. (US) 1989-10-04 EP disclosed
WO-1989003390-A1 SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY BODOR NICHOLAS S (US) 1989-04-20 WO disclosed
US-4710495-A Soft steroids having anti-inflammatory activity OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1987-12-01 US disclosed
JP-S5925373-A SULFONATE DERIVATIVE KYOTO YAKUHIN KOGYO KK 1984-02-09 JP disclosed